Comparison of Simvastatin Versus Simvastatin/Ezetimibe on Small Dense Low -Density Lipoprotein (LDL)
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
Both simvastatin 40 mg and simvastatin/ezetimibe 10/10 mg result in low-density lipoprotein
cholesterol (LDL-C) reductions of approximately the same magnitude. However, the differential
effects of these two treatment options on small dense LDL-C (sdLDL-C) concentration have not
been assessed.
The aim of the present study is to compare the effects of simvastatin 40 mg versus
simvastatin/ezetimibe 10/10 mg on sdLDL-C concentration. The primary efficacy endpoint will
be changes in LDL subfraction profile (i.e. mean LDL particle size, sdLDL-C levels) at 3
months after treatment initiation.